Lexeo基因疗法LX2020中期数据积极:高剂量组心律失常负担平均降80%,FDA对加速批准路径持开放态度

总部位于纽约的临床阶段生物技术公司 Lexeo Therapeutics(纳斯达克:LXEO)11月16日宣布,其基因疗法候选药 LX2020 治疗 PKP2 致心律失常性心肌病(PKP2-ACM)的 HEROIC-PKP2 一/二期临床试验取得积极中期数据,高剂量组患者的心律失常负担明显下降,美国食品药品监管局(FDA)对该药走加速批准路径的关键研究设计持开放态度。
这项试验共给药10名患者,其中低剂量组3人、高剂量组7人。截至2026年10月15日的数据截止日,9名患者随访已满12个月,其余1人随访9个月。在最新评估时,高剂量组患者的非持续性室性心动过速(NSVT)相对基线平均减少80%,7人中有6人改善;室性早搏(PVC)负担平均减少44%,7人中有5人改善。高剂量组多数患者的心脏磁共振检查显示心功能稳定或改善,心肌活检显示 PKP2 蛋白表达随剂量增加。
安全性方面,LX2020 在10名患者中总体耐受良好,没有观察到具临床意义的补体激活,也没有患者退出研究。高剂量组此前披露的肝功能指标升高已按试验方案处理成功,没有并发症或住院。此前披露的一例3级严重不良事件为给药3个月后出现的室性心动过速,公司称其与该病的自然病程一致,患者经抗心律失常药物治疗后出院、无需其他干预。
监管方面,FDA 表示对在加速批准关键研究中以指南定义的 NSVT 作为主要替代终点持开放态度。Lexeo 预计在2027年上半年定稿关键研究设计、统计分析计划与确证策略,2027年下半年启动关键研究。LX2020 此前已获 FDA 的再生医学先进疗法、孤儿药与快速通道资格认定。
PKP2 基因突变是致心律失常性心肌病最常见的遗传病因,约占病例的一半,美国估计约有6万人受影响。LX2020 旨在把功能完整的 PKP2 基因递送到心肌细胞,从病因层面恢复细胞间黏附。
Lexeo 同日公布2026年第三季度业绩:净亏损3,830万美元、每股亏损0.43美元;截至9月30日,公司现金、现金等价物与有价证券投资合计2.191亿美元,公司称可支撑运营至2028年。
(来源:Lexeo Therapeutics)
Lexeo Gene Therapy LX2020 Cuts Arrhythmia Burden 80% in High-Dose Cohorts as FDA Opens Door to Accelerated Approval Path
Lexeo Therapeutics (Nasdaq: LXEO), a New York-based clinical-stage biotechnology company, announced on November 16 that its gene therapy candidate LX2020 showed positive interim data in the HEROIC-PKP2 Phase I/II trial in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM), with a marked reduction in arrhythmia burden in the high-dose cohorts and a U.S. Food and Drug Administration (FDA) signal open to an accelerated approval pathway.
Ten participants have been dosed in the trial, including three in the low-dose cohort and seven in the high-dose cohorts. As of the October 15, 2026 data cutoff, nine participants had reached at least 12 months of follow-up and the remaining participant nine months. At the latest assessment, participants in the high-dose cohorts achieved an 80% mean reduction in non-sustained ventricular tachycardia (NSVT) relative to baseline, with six of seven improving, and a 44% mean reduction in premature ventricular contraction (PVC) burden, with five of seven improving. Cardiac MRI showed stabilization or improvement in cardiac function in the majority of high-dose participants, and cardiac biopsies showed dose-dependent increases in PKP2 protein expression.
LX2020 was generally well tolerated across the ten participants, with no clinically significant complement activation and no discontinuations. Previously disclosed elevations in liver function tests in the high-dose cohorts were treated successfully under the protocol with no complications or hospitalizations. One previously disclosed Grade 3 serious adverse event of ventricular tachycardia, observed three months after dosing, was described as consistent with the natural course of PKP2-ACM; the participant was treated with anti-arrhythmic medication and discharged with no additional intervention.
On the regulatory path, the FDA is open to the use of guideline-defined NSVT as a primary surrogate endpoint in a pivotal study supporting accelerated approval. Lexeo expects to finalize the pivotal study design, statistical analysis plan and confirmatory strategy in the first half of 2027 and to initiate the pivotal study in the second half of 2027. LX2020 has previously received Regenerative Medicine Advanced Therapy, Orphan Drug and Fast Track designations from the FDA.
Mutations in the PKP2 gene are the most common genetic cause of arrhythmogenic cardiomyopathy, accounting for about half of cases and affecting an estimated 60,000 people in the United States. LX2020 is designed to deliver a functional, full-length PKP2 gene to cardiomyocytes to address the underlying biology of the disease.
Lexeo also reported third-quarter 2026 results the same day: a net loss of $38.3 million, or $0.43 per share. As of September 30, cash, cash equivalents and investments totaled $219.1 million, which the company said is expected to fund operations into 2028.
(Source: Lexeo Therapeutics)
来源:Lexeo Therapeutics
发布:GSM·美国(发布链接)
图片来源:图:美国食品药品监管局(FDA)总部大楼入口。FDA 官方图,公共领域,经 Wikimedia Commons。 / Photo: Entrance of the U.S. Food and Drug Administration headquarters. FDA official photo, public domain, via Wikimedia Commons.
GSM Global · 本篇英文版 English edition of this story

